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2004 Update-180-Day Exclusivity Under the
Hatch-Waxman Amendments to the Federal Food,
Drug, and Cosmetic Act
ERiA KING LIETZAN *
This article updates the author's previously published article on the topic,' provides
some insight into recent events in this area of the law, and specifies a few minor items
that were noted incorrectly in the earlier work.
I. DR. REDDY'S LABORA ORES-EXCLUSRVITY IN THE EVENT
OF PATENT ExPIRY
On October 14, 2003, a federal district court in New Jersey found that Dr. Reddy's
Laboratories was not entitled to share Andrx's 180-day exclusivity for generic omeprazole
(marketed as Prilosec® by Astra Zeneca).2 The case as a whole does not add significantly
to 180-day exclusivity jurisprudence, but it is notable in at least one respect. Although
Andrx was the first to file a paragraph IV certification on ten of the eleven patents for the
40 mg version listed byAstra Zeneca, Dr. Reddy's was the first to file a paragraph V on the
tenth (Andrx had filed a paragraph Ill.) The patent expired after both abbreviated new drug
applications (ANDAs) were tentatively approved, but before either was finally approved.
The Food and Drug Administration (FDA) concluded that Dr. Reddy's "lost" its eligibility
for exclusivity when that patent expired, on the theory that the company was required to
amend its ANDA to convert the paragraph IV certification to a paragraph II under 21 C.F.R.
§ 314.94(a)(12)(viii)(C). The court noted that the agency had set forth this interpretation of
the statute at least twice prior to its decision on Dr. Reddy's application.' Dr. Reddy's
argued that FDA may not require generic applicants to amend their certifications prior to
final ANDA approval, and that an ANDA is eligible for exclusivity if it contains the
appropriate paragraph IV certification at the time of filing. The court found the statute
ambiguous on both points, however, and upheld the agency's decision.4
II. MYLAN AND TEVA CITIZEN PETITIONS-AUTHORIZED GENERICS
The generic industry continues to argue that "authorized generics" should be subject
to the exclusivity period awarded to the first generic applicant.' As described by FDA, the
* Ms. Lietzan is Assistant General Counsel, Pharmaceutical Research and Manufacturers of
America (PhRMA) in Washington, D.C.
See Erika King Lietzan, A Brief History of 180-Day Exclusivity Under the Hatch- Waxman
Amendments for the Federal Food, Drug, and Cosmetic Act, 59 FOOD & DRUG L.J. 287 (2004).
2 Dr. Reddy's Labs., Inc. v. Thompson, 302 F. Supp. 2d 340 (D.N.J. 2003).
3 Id. at 351 (citing 59 Fed. Reg. 50,338, 50,348 (Oct. 3, 1994) ("a patent is deemed to be
relevant until the end of the term of the patent or applicable 180-day period, whichever occurs first")
and FDA Response to APP and Pharmachemie Citizen's Petitions, 99P-1271/PDN1 (Aug. 2, 1999)
(on file with author)). The Dr. Reddy's court characterized the latter as stating that "because exclu-
sivity cannot extend beyond the expiration of a patent, an ANDA applicant who is first to file a
paragraph IV certification on a patent loses its eligibility based upon that patent when the patent
expires before either of the triggering events occurs."
4 Id. at 354-55.
1 See Lietzan, supra note 1, at 314.
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marketing of "authorized generics" is the "marketing of a product approved under a new
drug application (NDA), by that NDA holder, under that NDA, but at a lower price and not
under the 'brand' name, possibly through a different channel of distribution."6 As the
agency notes, these arrangements date back more than ten years.7 Nevertheless, generic
manufacturers argue now that distribution of authorized generics during the 180-day
exclusivity period is "anticompetitive" because it diminishes the value of the exclusivity
incentive. The original article noted a citizen petition filed by Mylan Pharmaceuticals in
February 2004. Teva Pharmaceuticals USA, Inc., submitted a similar citizen petition in
June, regarding an authorized generic of Pfizer's Accupril® (quinapril hydrochloride).8 On
July 2, FDA denied both petitions.' Among other things, the agency wrote that "FDA
does not regulate drug prices and has no legal basis on which to prevent an innovator
company from marketing its approved NDA product at a price that is competitive with that
charged by a first generic applicant to the market."'" Mylan promptly filed a court case
against the agency in the Northern District of West Virginia."I Shortly after oral argument,
it withdrew the suit.'2 Teva filed suit on August 20 in the District of Columbia against FDA,
seeking review of FDA's denial of its citizen petition. 3 In its amended complaint filed
October 8, Teva also named Pfizer and its subsidiary Greenstone Ltd. as defendants,
seeking to enjoin the launch of a generic version of Pfizer's Neurontin® (gabapentin) by
Greenstone. Greenstone launched the product on October 8,14 and, in an oral ruling on
October 13, the court denied Teva's motion for a temporary restraining order. The case is
still pending, but both Senator Hatch and Representative Waxman have stated that Con-
gress likely will look at the issue in the spring."
III. PFIZER CITIZEN PETITION-TRANSFER AND WAIVER OF
180-DAY EXCLUSIVITY
On May 11, 2004, Pfizer submitted a citizen petition to FDA asking the agency to
"acknowledge" that 180-day exclusivity cannot lawfully be waived or transferred. 6
6 FDA Response to Teva and Mylan Citizen Petitions, 2004P-0075/PDNl and 2004P-0261/
PDN1 (July 2, 2004) at 2, available at http://www.fda.gov/ohrms/dockets/dailys/04/july04/07070 4 /
04p-0261-pdn0001.pdf (last accessed Oct. 26, 2004).
Id. at 5 n.9.
Teva Pharmaceuticals USA, Inc., Citizen Petition, 2004P-0261/CP1 (June 9, 2004), available
at http://www.fda.gov/ohrms/dockets/dailys/04/JuneO4/06 1004/04p-0261 -cpOOOO 1-01-volt .pdf (last
accessed Oct. 26, 2004).
9 FDA Response to Teva and Mylan Citizen Petitions, 2004P-0075/PDN1 and 2004P-0261/
PDN1 (July 2, 2004), available at http://www.fda.gov/ohrms/dockets/dailys/04/julyO4/07070 4 /O4 p-
0261-pdn000l.pdf (last accessed Oct. 26, 2004).
"0 Id. at 2.
"1 Mylan Pharms., Inc. v. Food and Drug Admin., Case No. 1:04cv174 (N.D. W.Va. filed Aug. 4,
2004).
12 Notice of Voluntary Dismissal without Prejudice, Mylan Pharms., Inc. v. Food and Drug
Admin., Case No. 1:04cv174 (N.D. W.Va. Aug. 30, 2004). Trade press reported that "[t]he judge
seemed to indicate that Mylan might not be able to get FDA to act under the FDC Act because the law
is silent on the issue." Mylan Drops Authorized Generics Suit Against FDA, INSIDE WASHINGTON'S FDA
WEEK, Sept. 3, 2004, at 2.
13 Teva Pharms. USA, Inc. v. Crawford, Case No. 1:04cv01416 (D.D.C. filed Aug. 20, 2004).
Private litigation also is pending in California state court. In March 2004, Mylan sued both Procter
& Gamble and fellow generic manufacturer Watson Pharmaceuticals, which is marketing an autho-
rized generic of P&G's Macrobid ® (nitrofurantoin). Mylan Pharms., Inc. v. Procter & Gamble Co.,
Case No. CGC-04-429860 (Cal. Super. Ct. filed Mar. 23, 2004).
'4 "Authorized" Generics are "Legitimate Business Strategy, " Pfizer Says, F-D-C REP. ("The
Pink Sheet"), Oct. 18, 2004, at 24.
"S Congress Needs to Review "Authorized" Generics, Hatch and Waxman Agree, F-D-C RPr.
("The Pink Sheet"), Oct. 11, 2004, at 40.
16 Pfizer, Inc., Citizen Petition, 2004P-0227/CP1 (May 11, 2004), available at http://www.fda.gov/
ohrms/dockets/dailys/04/mayO4/051304/04p-0227-cpOOOOl-voll.pdf (last accessed Oct. 26, 2004).
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Pfizer argued, among other things, that the plain language of the statute does not permit
waiver or transfer, and that permitting exclusivity to be fully alienable encourages ANDA
applicants to file weak applications simply to vest a lucrative asset. On July 2, 2004, the
agency denied that citizen petition.17 FDA rejected the textual argument on the ground
that section 505(j)(5)(B)(iv) is ambiguous and can reasonably be interpreted to permit
waiver. Further, FDA added, the statute confers a private benefit to specific entities, and
in such situations judicial precedent supports inferring that the agency may allow an
alternative course of action more favorable to the beneficiary. Further, the agency noted,
allowing generic applicants to waive their exclusivity promotes competition by enabling
other generic applicants to market their products sooner.
The original article noted that in 1999, FDA proposed regulations pursuant to which, after
a triggering event, a first generic would be permitted to transfer its rights to another com-
pany.Is Prior to occurrence of the triggering event, however, the first generic would not be
permitted to do so. It could waive, or relinquish, the exclusivity entirely, but not selectively
waive, or transfer, the exclusivity to another applicant. The original article stated that with the
2002 withdrawal of the proposed regulations, the use of a triggering event as a threshold
requirement would not be implemented. FDA's response to Pfizer's 2004 citizen petition
makes it clear, however, that FDA continues to require a triggering event in order to distin-
guish between relinquishment and selective waiver. Indeed, the requirement of a triggering
event forms the basis of FDA's response to Pfizer's point about encouraging weak applica-
tions. "As to potential 'gaming,' if the first applicant could selectively waive [transfer] its
exclusivity at any time, the agency could reasonably expect the development of a 'market' for
180-day exclusivity, with a resulting increase in ANDA's submitted solely to claim exclusiv-
ity." The agency concluded, however, "that by permitting selective waiver [transfer] only
once the exclusivity is triggered, it can prevent 'gaming' of exclusivity, avoid unnecessary
exclusivity disputes, and still maintain exclusivity as an adequate incentive and reward."' 9
IV. TORPHARM-SHARED EXCLUSIVITY
As noted in the earlier article,20 on January 2 the U.S. District Court for the District of
Columbia entered judgment for TorPharm, declaring that FDA's decision to award shared
exclusivity to multiple ANDA applicants for the generic Paxil® (paroxetine hydrochlo-
ride) was contrary to the plain language of the Federal Food, Drug, and Cosmetic Act
(FDCA).2 1 The Department of Justice appealed, and the case is still pending. 2 Oral
argument was scheduled for December 2004.23
V. PUREPAC I---CONTROLLING DATE FOR EXCLUSIVITY PURPOSES, SHARED
EXCLUSIVITY
As noted in the original article,24 on January 20,2004, the D.C. Circuit affirmed a district
court decision that: a) the operative date for the filing of an amended certification is the
17 FDA Response to Pfizer Citizen Petition, 2004P-0227/PDN1 (July 2, 2004), available at
http://www.fda.gov/ohrms/dockets/dailys/04/julyO4/070704/04p-0227-pdnOOOl.pdf (last accessed Oct.
26, 2004).
IS See Lietzan, supra note 1, at 302.
'9 FDA Response to Pfizer Citizen Petition, supra note 17, n.5.
20 Lietzan, supra note 1, at 308.
21 See 2004 WL 64064 (D.D.C. Jan. 8, 2004).
22 Apotex, Inc. v. Food and Drug Admin., Case No. 04-5046 (D.C. Cir. notice of appeal filed Feb.
13, 2004).
23 Court Split on FDA "s Patent-by-Patent Approach to 180-Day Exclusivity, INSIDE WASHINGTON'S
FDA WEEK, June 11, 2004.
24 Lietzan, supra note 1, at 306-07.
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day that the certification is received by the agency, rather than the date that the certifica-
tion was mailed by the applicant, and b) because where a section viii statement is proper,
a paragraph IV certification is not, TorPharm's paragraph IV certification was improper and
the company was not eligible for exclusivity. Two additional points are worth making
about this case. First, with respect to the first ruling, the case involved only an amended
certification, and both the ruling and FDA's policy25 may be limited to that context. Sec-
ond, after the TorPharm decision discussed infra, this case spawned new litigation over
shared exclusivity and prompted a split of opinions within the same district court.
VI. APOTEX-SHARED EXCLUSIVITY
Purepac had been the first to challenge an earlier Warner-Lambert patent on Neurontin®.
Arguably, in light of the decision in the TorPharm (Paxil®) case-that there can be only one
exclusivity period for an innovator product, rather than patent-by-patent exclusivity-
Purepac's exclusivity already had run.26 On precisely this theory, Apotex brought suit against
FDA in April 2004, challenging FDA's failure to grant final approval ofApotex's ANDA for
generic gabapentin capsulesY.2 In a June 3 ruling from the bench, the court denied Apotex's
motion for a preliminary injunction, and granted the government's motion to dismiss.
28
Although the written order is spare, apparently the judge in open court disagreed with the
ruling in the TorPharm case, found the statute ambiguous, and concluded that the agency's
patent-by-patent approach was reasonable.29 Two federal judges from the same federal
district court have, therefore, ruled differently on shared exclusivity.3" Apotex appealed this
decision,3' and the case is still pending. The court of appeals likely will consolidate the two
shared exclusivity cases. The final decision will be relevant only to old ANDAs (those filed
before December 8, 2003, and those filed afterwards, if a paragraph V certification for the
listed drug was filed before December 8, 2003), because exclusivity under the statute as
amended in 2003 is product-by-product rather than patent-by-patent.
VII. RESPONSE TO Two CITIZEN PETITIONS-DISCLOSURE OF DATE OF
SUBMISSION
On March 2, FDA responded to citizen petitions that had been filed in 1999 and 2000,
by announcing that it would now disclose on its website the date on which the first
substantially complete generic drug application containing a challenge to a patent listed
for the innovator drug was submitted to the agency.32 The list of paragraph IV patent
23 And, therefore, id. at 290 (fourth bullet) and 291 (third bullet).
26 See Appeals Court Backs FDA: Purepac Gets Gabapentin 180-Day Award, INSIDE WASHINGTON'S
FDA WEEK, Jan. 23, 2004, at 3.
22 Apotex, Inc. v. Food and Drug Admin., I:04-cv-00605-ESH (D.D.C. filed Apr. 14, 2004).
28 Order, Apotex, Inc. v. Food and Drug Admin., 1:04-cv-00605-ESH (D.D.C. June 3, 2004); see
Court Split on FDA's Patent-by-Patent Approach to 180-Day Exclusivity, supra note 23.
29 See Court Split on FDA 's Patent-by-Patent Approach, supra note 23.
30 Another federal court-the New Jersey court in the Dr Reddy's case-has addressed FDA's
patent-by-patent approach to 180-day exclusivity, but it did not rule on FDA's policy of shared
exclusivity. See Dr. Reddy's Labs., 302 F. Supp. 2d at 340.
31 Apotex, Inc. v. Food and Drug Admin., Case No. 04-5211 (D.C. Cir. notice of appeal filed June 9, 2004).
32 Biovail Corp. Int'l, Citizen Petition, 99P-2778/CPI (July 27, 1999) (on file with author); Hyman,
Phelps, & McNamara, Citizen Petition, OOP-1556/CP1 (Oct. 4, 2000), available at http://www.fda.gov/
ohrms/dockets/dailys/00/ Oct00/100400/cp000Ol.pdf (last accessed Oct. 29, 2004); FDA Response to
Biovail and Hyman Phelps Citizen Petitions, OOP-1556/PAV1 (Feb. 27, 2004), available at http://www.fda.gov/
ohrms/dockets/dailys/04/marO4/030504/00p-1556-pavOO001-voll.pdf (last accessed Oct. 29, 2004); News
Release (P04-25), FDA, FDA Announces Measures to Improve Generic Drug Access (Mar. 2, 2004). Hyman
Phelps also had asked that the agency disclose the patents to which ANDA applicants have made paragraph
IV certifications, and the date of the first certification for each. FDA declined to do so, because the 2003
statutory amendments mooted the request. See FDA Response at 5-6 ("Eligibility for 180-day exclusivity for
applications governed by the amended statute no longer tums on individual patents, but is product-based.").
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certifications maintained on FDA's website now includes a column for "date of submis-
sion."33
VIII. TYPOGRAPHICAL CORRECTION
In the earlier article, the reference in footnote 29 to section 1 101(b)(3) of Pub. L. No. 108-
173 should be replaced with a reference to section 11 02(b)(3). The D.C. Circuit decision in
Inwood, cited in footnote 44, occurred in 1989, not 1998. And the citation at the top of page
299 to 21 C.F.R. § 214.107(c)(4) should be a citation to 21 C.F.R. § 314.107(c)(4).
31 See http://www.fda.gov/cder/ogd/ppiv.htm (last accessed Oct. 29, 2004).

